Intelligence / Healthtech / De Novo Grants / Fziomed, Inc.
Approvalsnovel device granted (FDA De Novo)17 Jun 2025
Fziomed, Inc.
17 Jun 2025: Novel device granted (FDA De Novo) · Oxiplex®. Recorded in the openFDA device 510(k) (De Novo decisions).
- Granted
- 17 Jun 2025
- Device
- Oxiplex®
- Specialty
- Orthopedic
- Product Code
- QVL
- Country
- United States
- Location
- San Luis Obispo, CA
- Submitted
- 2024-07-22
- Reference
- DEN240038
What this signal means
A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.
- 2 added in the 30 days to 19 Nov 2026.
- Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS
Find the decision makers at Fziomed, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Fziomed, Inc. in our registers.
More in Orthopedic
De Novo Grants
21 AugBrixton Biosciencesnovel device granted (FDA De Novo) · ReneuRx (Neural Ice)Approvals17 JulStryker Endoscopynovel device granted (FDA De Novo) · SportSuite Vision SoftwareApprovals6 JulSmith & Nephew, Inc.novel device granted (FDA De Novo) · TESSA Spatial Surgery System; INTELLIO Tablet (72205455)Approvals
Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.